SCHEMBL5313892

SCHEMBL5313892

CN(N)CCN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14126624 0.79
SCHEMBL11746601 0.79
SCHEMBL28651066 0.76
SCHEMBL25690276 0.74
SCHEMBL5573 0.72
SCHEMBL15075 0.72
SCHEMBL21791614 0.72
SCHEMBL18789236 0.72 CHRM2 (0.40)
SCHEMBL13872862 0.70
SCHEMBL23304293 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3844144-B1 NEW FUNCTIONALISED TETRAZENE COMPOUNDS ARIANEGROUP SAS (FR) 2023-12-13 EP claimed
EP-3844144-B1 NEW FUNCTIONALISED TETRAZENE COMPOUNDS ARIANEGROUP SAS (FR) 2023-12-13 EP disclosed
EP-3844144-B1 NEW FUNCTIONALISED TETRAZENE COMPOUNDS ARIANEGROUP SAS (FR) 2023-12-13 EP disclosed
US-20230174488-A1 SARS-COV-2 INHIBITORS HAVING COVALENT MODIFICATIONS FOR TREATING CORONAVIRUS INFECTIONS INSILICO MEDICINE IP LIMITED (HK) 2023-06-08 US disclosed
WO-2023072301-A1 PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE COMPOUND AND MEDICAL USE THEREOF 正大天晴药业集团股份有限公司 2023-05-04 WO disclosed
EP-3747883-A1 MONOCYCLIC B-LACTAM COMPOUND FOR TREATING BACTERIAL INFECTION Medshine Discovery Inc. (CN) 2020-12-09 EP disclosed
WO-2020043997-A1 NEW FUNCTIONALISED TETRAZENE COMPOUNDS ARIANEGROUP SAS (FR) 2020-03-05 WO disclosed
EP-2678035-B1 PHENALENE-1-ONE DERIVATIVES, METHOD FOR PRODUCING SAME AND USE THEREOF TRIOPTOTEC GMBH (DE) 2019-04-10 EP disclosed
CN-108283644-A To the instantaneous protection of normal cell during chemotherapy G1治疗公司 2018-07-17 CN disclosed
US-20170145012-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS FORMA THERAPEUTICS, INC. 2017-05-25 US disclosed
US-5741912-A DIAGNOSIS, THERAPY BRACCO INTERNATIONAL B.V. 1998-04-21 US disclosed
US-5665329-A Heteroatom-bearing ligands and metal complexes thereof BRACCO INTERNATIONAL B.V. 1997-09-09 US disclosed
US-5656254-A Polyaza heteroatom-bearing ligands and metal complexes thereof for imaging or radiotherapy BRACCO INTERNATIONAL B.V. 1997-08-12 US disclosed
US-5627286-A Heteroatom-bearing ligands and metal complexes thereof BRACCO INTERNATIONAL B.V. 1997-05-06 US disclosed
US-5608110-A Heteroatom-bearing ligands and metal complexes thereof BRACCO INTERNATIONAL B.V. 1997-03-04 US disclosed
CN-1099388-A Heteroatom-bearing ligands and metal complexes thereof BRISTOL MYERS SQIBB COMPANY (US) 1995-03-01 CN disclosed
EP-0629617-A1 Heteroatom-bearing ligands and metal complexes thereof BRACCO International B.V. (NL) 1994-12-21 EP disclosed
US-4268486-A REACTING WITH A HYDRAZINE COMPOUND AND SEPARATING TRIVALENT CHROMIUM COMPOUNDS OLIN CORPORATION (US) 1981-05-19 US disclosed
US-4002625-A HERBICIDES, INSECTICIDES, ANTIMICROBIALS THE DOW CHEMICAL COMPANY (US) 1977-01-11 US disclosed
US-3962113-A METHOD FOR ACCELERATING OXYGEN REMOVAL EMPLOYING AN AQUEOUS SOLUTION OF AN ALKYL HYDRAZINE OLIN CORPORATION (US) 1976-06-08 US disclosed